| Independent Reports (Showing 1 to 10 of 22) |
Release Date ![[down]](http://us.i1.yimg.com/us.yimg.com/i/fi/down.gif) |
Contributor |
Author |
Title |
Pages |
Price |
More Info |
| 19-Jun-13 | ValuEngine, Inc. | N/A | ValuEngine Industry Report for Medical-biomed/genetics | 18 | $207 | View Abstract |
| 17-Jun-13 | Market Edge | N/A | Market Edge Equity Research Report | 4 | $10 | View Abstract |
| 15-Jun-13 | S&P Capital IQ Quantitative Report | N/A | Keryx Biopharmaceuticals | 6 | $69 | View Abstract |
| 15-Jun-13 | Pechala's Reports | Frantisek Pechala | KERYX BIOPHARMACEUTICALS INC (KERX) 12-months forecast | 1 | $15 | View Abstract |
| 14-Jun-13 | Wright Reports | N/A | Wright Industry Averages: Pharmaceuticals & Biotechnology (Global) | 105 | $1207.50 | View Abstract |
| 14-Jun-13 | Wright Reports | N/A | Wright Industry Averages: Pharmaceuticals & Biotechnology (North America) | 78 | $897 | View Abstract |
| 14-Jun-13 | Wright Reports | N/A | Wright Industry Averages: Pharmaceuticals & Biotechnology (United States) | 77 | $885.50 | View Abstract |
| 14-Jun-13 | Ford Investor Services, Inc. | N/A | Industry Value Graph: BIOD , INFI , KERX , PBYI , SNTA -- DRUGS | 3 | $34.50 | View Abstract |
| 14-Jun-13 | Ford Investor Services, Inc. | N/A | Value Graph: KERYX BIOPHARM -- KERX | 1 | $11.50 | View Abstract |
| 14-Jun-13 | Jefferson Research | N/A | Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of KERYX BIOPHARMACEUTICALS INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. | 11 | $20 | View Abstract |